WBH Advisory Inc. Decreases Stock Position in Pfizer Inc. $PFE

WBH Advisory Inc. cut its position in Pfizer Inc. (NYSE:PFE) by 9.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,130 shares of the biopharmaceutical company’s stock after selling 1,809 shares during the quarter. WBH Advisory Inc.’s holdings in Pfizer were worth $415,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in PFE. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer in the first quarter valued at $27,000. North Capital Inc. bought a new position in Pfizer during the 1st quarter valued at $28,000. Bayforest Capital Ltd bought a new position in Pfizer during the 1st quarter valued at $28,000. Harbor Asset Planning Inc. bought a new position in Pfizer during the 2nd quarter valued at $29,000. Finally, Horizon Financial Services LLC bought a new position in Pfizer during the 1st quarter valued at $35,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.7%

Shares of NYSE:PFE opened at $24.68 on Tuesday. The stock has a market capitalization of $140.33 billion, a price-to-earnings ratio of 13.13, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $29.22. The company’s fifty day moving average is $24.89 and its two-hundred day moving average is $24.12. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter last year, the company earned $0.60 EPS. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research analyst reports. UBS Group reiterated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Morgan Stanley reduced their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Bank of America increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Finally, Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.